FDA Approves Tocilizumab for the Treatment of CAR T Cell-Induced Cytokine Release SyndromeNalleyCatlin
In a retrospective analysis of pooled outcome data from multiple clinical trials 45 patients were treated with tocilizumab 8 mg/kg (12 mg/kg for patients less than 30 kg) with or without additional high-dose corticosteroids for severe or life-threatening CAR T-cell-induced CRS. A median of ...
Treatment of Cytokine release syndrome caused by car-t cell therapy •••••••••••• •••••• ••••••••• ••••••••• Treatment of Giant cell arteritis (gca) •••••••••••• ...
Tocilizumab only: management of CAR T cell-induced severe or life-threatening CRS in adults and pediatric patients ≥2 years of age.Can be used alone or in combination with corticosteroids.Do not use concomitantly with other biologic DMARDs; concomitant use has not been studied, and there is ...
Tocilizumabis a recombinanthumanized monoclonal antibodyof theIgG1class. It acts against Interleukin 6 (IL-6) receptor. It is recommended for use in cytokine storms due to CAR-T cell therapy, severerheumatoid arthritis, andgiant cell arteritis. It was first studied in COVID-19 patients in Wuhan...
Moreover, tocilizumab is additionally FDA approved to manage CRS in patients who receive CAR T-cell therapy [17], [18], with which our center has experience. Tocilizumab was approved in China in March 2020 for the treatment of patients with COVID-19 and severe pulmonary disease associated ...
Chimeric antigen receptor therapy (CAR-T) T cell-induced severe cytokine release syndrome (CRS) Severe or life-threatening cytokine release syndrome associated with SARS-CoV-2 FORMS FORMS FORMS brand name preparation manufacturer route form dosage^ cost* Actemra Tocilizumab Genentech IV Vial 80mg/4mL...
mediated sepsis (Source).Chimeric antigen receptor T-cell therapy (CAR-T therapy)can causeCRSand induce the massive and coordinated release of pro-inflammatory cytokines. This unintended side effect of cancer cell therapy can be treated with tocilizumab in patients over the age of two with severe...
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. PMID: 31320380 Current concepts in the diagnosis and management of cytokine release syndrome. PMID: 24876563 KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. PMID...
Toxicities of CD19 CAR-T cell immunotherapy. PMID: 30784102 Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer. PMID: 36636447 Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. PMID: 29...